Ability Biologics is pioneering the development of next-generation targeted biotherapeutics through its proprietary AbiLeap™ discovery platform. This innovative platform leverages artificial intelligence to create logic-enabled antibodies that can selectively engage with specific immune pathways. By utilizing one of the largest databases of antibody-antigen interactions, Ability aims to generate fully human antibodies that exhibit exquisite selectivity and affinity. These antibodies are designed to respond to environmental signals within the cellular microenvironment, allowing for targeted therapeutic applications in areas such as oncology and autoimmune diseases. The focus on developing best-in-class immune modulators underscores the company's commitment to addressing significant unmet medical needs with safer and more effective treatments.

The AbiLeap™ platform not only enhances the specificity and selectivity of antibody therapeutics but also streamlines the manufacturing and development processes. By employing established IgG formats, Ability Biologics aims to simplify the complexities often associated with drug development, thereby accelerating the timeline for bringing new therapies to clinical settings. The company is actively advancing several preclinical antibody candidates and plans to conduct human proof-of-concept clinical trials to validate their therapeutic potential. With a strong management team experienced in immunology and drug development, Ability Biologics is positioned to become a leader in the biotherapeutic targeting space, focusing on creating potent and selective antibody therapeutics for a range of critical health challenges.

Canada

Ability Biologics is dedicated to developing innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases. The company utilizes its powerful AbiLeap™ discovery engine, which combines massively parallel, continuously learning AI with advanced cell targeting technology, to develop the most potent and selective antibody therapeutics for areas of great unmet need.

Ability Biologics

Company Details